ABCSG 61 / TEODOR Overview
Neoadjuvant TrEatment Optimization driven by ctDNA and endOcrine Responsiveness
A prospective, randomized, controlled, open-label multicenter phase II study investigating neoadjuvant endocrine therapy versus chemotherapy in HR-positive, HER2-negative, ctDNA-negative and endocrine responsive early and locally advanced breast cancer
| Study Start: | Q3/2025 |
| Coordinating Investigators: | Michael Gnant, Vienna Daniel Egle, Innsbruck |
| Participants: | 256 (national) |
| Study Design: (Click to enlarge) |
 |
Share on